Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-na ïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial]

New strategies to increase measles and rubella vaccine coverage, particularly in low- and middle-income countries, are needed if elimination goals are to be achieved. With this regard, measles and rubella vacc...

Source: Trials - September 14, 2022 Category: General Medicine Authors: Ikechukwu Adigweme, Edem Akpalu, Mohammed Yisa, Simon Donkor, Lamin B. Jarju, Baba Danso, Anthony Mendy, David Jeffries, Abdoulie Njie, Andrew Bruce, Michael Royals, James L. Goodson, Mark R. Prausnitz, Devin McAllister, Paul A. Rota, Sebastien Henry & he Tags: Study protocol Source Type: research